IRMD vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDRE
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Iradimed vs.
Warby Parker (NYSE:WRBY) and Iradimed (NASDAQ:IRMD) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.
93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 26.5% of Warby Parker shares are owned by insiders. Comparatively, 37.1% of Iradimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Iradimed has lower revenue, but higher earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed received 217 more outperform votes than Warby Parker when rated by MarketBeat users. Likewise, 65.23% of users gave Iradimed an outperform vote while only 42.11% of users gave Warby Parker an outperform vote.
Warby Parker presently has a consensus target price of $21.92, indicating a potential downside of 8.76%. Iradimed has a consensus target price of $72.00, indicating a potential upside of 28.02%. Given Iradimed's stronger consensus rating and higher possible upside, analysts plainly believe Iradimed is more favorable than Warby Parker.
In the previous week, Warby Parker had 3 more articles in the media than Iradimed. MarketBeat recorded 9 mentions for Warby Parker and 6 mentions for Iradimed. Warby Parker's average media sentiment score of 0.54 beat Iradimed's score of 0.47 indicating that Warby Parker is being referred to more favorably in the media.
Iradimed has a net margin of 26.26% compared to Warby Parker's net margin of -4.39%. Iradimed's return on equity of 24.12% beat Warby Parker's return on equity.
Warby Parker has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Summary
Iradimed beats Warby Parker on 12 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 2/22/2025 by MarketBeat.com Staff
